Left Atrial Appendage Closure

1. Percutaneous LAA Closure Devices and Trial Results

   1. Novel Percutaneous LAA Closure Devices in Clinical or Preclinical Trials

      • Sameer Gafoor, Luisa Heuer, Jennifer Franke, Markus Reinartz, Stefan Bertog, Laura Vaskelyte et al.

      Pages 233-243

   2. Concomitant Left Atrial Appendage Closure and Catheter Ablation of Atrial Fibrillation

      • Claudio Tondo, Gaetano Fassini

      Pages 245-257

2. Post-procedural Management and Issues

   1. Front Matter

      Pages 259-259

      PDF

   2. Procedural Complications and Management

      • Ivan P. Casserly, Kevin Walsh, Jacqueline Saw

      Pages 261-273

   3. Antiplatelet and Anticoagulant Strategies Following Left Atrial Appendage Closure

      • Louisa Malcolme-Lawes, Prapa Kanagaratnam

      Pages 275-282

   4. Device-Related Thrombi, Residual Leaks, and Consequences

      • Fabian Nietlispach, Bernhard Meier

      Pages 283-292

3. Back Matter

   Pages 293-300

   PDF

Percutaneous left atrial appendage (LAA) closure is an emerging technology for thromboembolic prevention in patients with atrial fibrillation (AF). The first human implantation of an LAA device occurred in 2001, and since then four devices have received CE mark approval. These devices are being widely used in Europe for LAA closure in patients who are poor candidates for long-term oral anticoagulation. In the US, the WATCHMAN device (Boston Scientific) is anticipated to receive FDA approval imminently for AF patients who are warfarin-eligible. This approval is projected to significantly expand the indications for LAA closures worldwide. Thus, the volume of procedures is anticipated to escalate. This book discusses the epidemiology of AF as a cause of stroke; the use of LAA closure in the reduction of thromboembolism with AF; early surgical approaches and novel surgical devices for LAA closure; and current percutaneous approaches and devices available for LAA closure. The emphasis of this book is on percutaneous technical approaches and contemporary trial results on the leading devices (PLAATO, WATCHMAN, Amplatzer Cardiac Plug, and LARIAT). It also reviews unapproved devices in development, in both clinical and pre-clinical phases.

• Amplatzer Cardiac Plug
• LARIAT device
• WATCHMAN device
• atrial fibrillation
• left atrial appendage closure
• thromboembolic prevention

• Vancouver General Hospital, University of British Columbia, Vancouver, Canada

  Jacqueline Saw

• Cardiovascular Intervention Center Research, Cedars-Sinai Medical Center, Los Angeles, USA

  Saibal Kar

• Scripps Translational Science Institute, Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, USA

  Matthew J. Price

Jacqueline Saw, MD, FRCPC, FACC, FSCAI Clinical Associate Professor University of British Columbia Head, VGH Cardiology Clinical Trials Research Program Director, VGH Interventional Cardiology Fellowship Vancouver General Hospital 2775 Laurel Street, Level 9 Vancouver, V5Z1M9, British Columbia Canada Saibal Kar, MD, FACC Director, Interventional Cardiology Research Cedars-Sinai Medical Center 8631 W. 3rd Street, #415E Los Angeles, CA 90048 Matthew J. Price, MD, FACC, FSCAI Director, Cardiac Catheterization Laboratory Division of Cardiovascular Diseases Scripps Clinic Assistant Professor Scripps Translational Science Institute 10666 North Torrey Pines Road, Maildrop S1056 La Jolla, CA 92037 Jacqueline Saw is the editor of Carotid Artery Stenting: The Basics (978-1-60327-313-8, 2009) and Handbook of Complex Percutaneous Carotid Intervention (978-1-58829-605-4, 2007), both of which are volumes in the Contemporary Cardiology series.

Policies and ethics